Lectura recomendada por el Dr. Mauricio Luongo.
Conferencia 2024: “Presente de los tratamientos con Inmunoradioterapia.»
- Autores: Chiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian et al.
- Fuente: Lancet 2019; 393: 2051–58.
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block
[CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
Paper-02.-PIIS0140673623018573